Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
about
WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lungHuman epididymis protein-4 (HE-4): a novel cross-class protease inhibitorHE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesSerum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cystsCurrent clinical application of serum biomarkers to detect ovarian cancerGlycosylation-Based Serum Biomarkers for Cancer Diagnostics and PrognosticsIn 2014, can we do better than CA125 in the early detection of ovarian cancer?The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerThe diagnostic accuracy of HE4 in lung cancer: a meta-analysisIdentification of quiescent, stem-like cells in the distal female reproductive tractProteomics of ovarian cancer: functional insights and clinical applicationsAntimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implicationsTowards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studiesComprehensive analysis of HE4 expression in normal and malignant human tissues.Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cellsPlasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.A molecular signature of gastric metaplasia arising in response to acute parietal cell lossProtein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.The role of proteomics in the diagnosis and treatment of ovarian cancer.Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyOverexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumUse of a Symptom Index, CA125, and HE4 to predict ovarian cancer.Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients: correlation with concentration in ascites.Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Ovarian cancer biomarkers for molecular biosensors and translational medicine.Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.Establishment of novel in vitro mouse chief cell and SPEM cultures identifies MAL2 as a marker of metaplasia in the stomach.Serum Human Epididymis Protein 4 (HE4) in the Differential Diagnosis of Peritoneal Tuberculosis: A Report of Two Cases.Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYCElevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancerHE4 as a biomarker for ovarian and endometrial cancer management.HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
P2860
Q21284411-207A781B-04D8-498B-8CE9-8727EAEA15F0Q24303274-21AEF6FE-D731-44E4-A69F-3E77ECDC1246Q24634978-01DCCC9F-37C9-4463-8FCC-0AAFA49261A6Q24651331-DA02657D-3798-4406-B8A3-FB7D162751AEQ26768709-19AF7C9B-FD11-4FA5-9DAD-05B933346A23Q26778227-B2CE628A-60A7-4FA9-9D08-91B4379F4810Q26825152-134BAB6C-7F92-47BD-9890-19961EA6B924Q26992102-CDD1FF38-FB2A-4A7B-81DF-1A5BCD0971B9Q26996829-DDFECC3E-41BB-415B-A578-04DCB5C590F7Q27027383-387D1A6A-6B24-4376-80EB-46F5AADCF044Q27334330-B0C0FEDE-2CB0-4049-B495-FEAF31B4A7A3Q28082632-2CCFD2D7-D9E6-4045-9DF0-2AD73C6FAB49Q28087327-73871682-15D8-4B9B-A516-0744AA47BFDDQ30414041-457B8840-D06A-44D5-9EAE-2B1811A630BCQ30440200-6AD80813-E8E8-48D7-8274-75BC28387E8BQ30597866-5472BC08-FD00-4AC6-B145-2CBC932B5580Q32173966-8C403132-D317-421C-A133-B2529909ADD4Q33317849-9DEF7F3F-4CB2-4863-AC80-18B0F20254DAQ33503319-BA4003DE-5E28-4F9B-A1B4-CFB7F56C03B8Q33508672-5D789F77-0FEC-4D7C-8989-514A9528A118Q33511864-E51D752D-A49C-4F47-8995-1CF5E3466A86Q33574039-8774944C-2140-40A3-8A82-F100A07A104EQ33622587-ADDA6E13-67DF-4E3A-A113-18E4D3743C0EQ33624809-33BB6071-4139-4A04-A13A-91DA235ECC9BQ33653799-C9169A40-0698-4844-A3D8-1F27BA482015Q33690390-59E6C975-6B86-4E19-952E-97A0A67ED2E7Q33733786-B355ECF3-F8F7-4E52-808D-29C441109988Q33808368-7FA4DE41-89DC-4623-81B4-1A35F9947166Q33946367-3E8BB3E6-AE34-4F3F-8FF1-9750D7B78BC9Q33955266-94C52877-AB66-4176-8B13-2469937881FAQ34150097-51891CFD-4C99-443B-BD1C-1BC672A6F58AQ34308808-DE51986D-714C-44D2-B175-B3319414EAE3Q34356044-BE71054A-1588-4055-88AD-68F259D94D1CQ34378962-B8507A13-D7E5-423B-8E36-2EF52A359EC5Q34384802-C6443AD7-6D5B-4E5C-910D-75EDEA85A225Q34431321-ECE0F238-EAAB-48A6-B028-7F7C00D9BDBCQ34526484-03843685-A1C9-4DC7-930E-DF0E14FB5518Q34611530-74B8C84B-1380-44B3-9A8F-19D35CCCC330Q34621826-34A5692F-AE82-46B2-9C79-7F35B277C453Q34675023-27339599-ABBA-4466-8FAD-04CB1FF5D4AD
P2860
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@ast
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@en
type
label
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@ast
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@en
prefLabel
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@ast
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@en
P2093
P1433
P1476
Human epididymis protein 4 (HE ...... dometrioid ovarian carcinomas.
@en
P2093
Christopher P Crum
Hans Henning von Horsten
Jonathan L Hecht
Ronny Drapkin
Samuel C Mok
William R Welch
Yafang Lin
P304
P356
10.1158/0008-5472.CAN-04-3924
P407
P577
2005-03-01T00:00:00Z